Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2021
Journal Article
Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w)
Burgess, M., Chen, Y. C.E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2021). Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w). Oncogene, 40 (6), 1203-1203. doi: 10.1038/s41388-020-01619-y
2021
Journal Article
SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients
Chen, Yu-Chen Enya, Burgess, Melinda, Mapp, Sally, Mollee, Peter, Gill, Devinder, Blumenthal, Antje and Saunders, Nicholas A. (2021). SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients. Frontiers in Immunology, 11 610523, 1-12. doi: 10.3389/fimmu.2020.610523
2021
Journal Article
Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial
Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John and Weisel, Katja (2021). Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial. Journal of Clinical Oncology, 39 (3), 227-237. doi: 10.1200/JCO.20.01370
2021
Journal Article
The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia
Murali, Aarya, Cross, Donna and Mollee, Peter (2021). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia. Blood Cancer Journal, 11 (1) 6, 6. doi: 10.1038/s41408-020-00401-3
2021
Journal Article
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft
Rees, Matthew J., Mollee, Peter, Ng, Jun Yen, Murton, Alex, Gonsalves, Jose Filipe, Panigrahi, Ashish, Beer, Hayley, Loh, Joanna, Nguyen, Philip, Hunt, Sam, Jina, Hayden, Wayte, Rebecca, Sutrave, Gaurav, Tan, Jocelyn, Abeyakoon, Chathuri, Chee, Ashlyn, Augustson, Bradley, Kalro, Akash, Lee, Cindy, Agrawal, Shivam, Churilov, Leonid, Chua, Chong Chyn, Lim, Andrew Boon Ming, Zantomio, Daniela and Grigg, Andrew (2021). The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transplantation, 56 (9), 2152-2159. doi: 10.1038/s41409-021-01300-2
2021
Journal Article
A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma
Tobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866
2021
Journal Article
Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting
Smith, Joel D, Wijeratne, Nilika, Schneider, Hans G, de Malmanche, Theo, Hissaria, Pravin, Toit, Stephen Du, Chiu, Weldon, Boyder, Conchita, Morison, Ian M, Tseng, Anfernee, Glegg, Kaye, Wienholt, Louise, Mollee, Peter and on behalf of the AACB/RCPA Monoclonal Gammopathy Working Party (2021). Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. Clinical Biochemist Reviews, 42 (1), 11-16. doi: 10.33176/AACB-21-00001
2020
Journal Article
Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices
Ellis, Marc L., Okano, Satomi, McCann, Andrew, McDowall, Angela, Van Kuilenburg, Rosita, McCarthy, Alexandra L., Joubert, Warren, Harper, John, Jones, Mark and Mollee, Peter (2020). Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal, 50 (12), 1475-1482. doi: 10.1111/imj.14780
2020
Conference Publication
Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study
Sanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y., Tromp, Brenda, Weiss, Brendan M. ... Wechalekar, Ashutosh D. (2020). Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-139438
2020
Conference Publication
A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma
Tobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590
2020
Conference Publication
Management and outcomes of testicular lymphoma in the rituximab era at an Australian tertiary centre
Murali, Aarya, Boyle, Stephen, Mollee, Peter and Hapgood, Greg (2020). Management and outcomes of testicular lymphoma in the rituximab era at an Australian tertiary centre. 62nd ASH Annual Meeting, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-138440
2020
Conference Publication
The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia
Murali, Aarya, Cross, Donna and Mollee, Peter (2020). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. AMSTERDAM: American Society of Hematology. doi: 10.1182/blood-2020-140966
2020
Conference Publication
The role of whole body STIR MRI in assessing first biochemical relapse in patients with myeloma
Rowland, James and Mollee, Peter (2020). The role of whole body STIR MRI in assessing first biochemical relapse in patients with myeloma. 62nd ASH Annual Meeting, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-139194
2020
Conference Publication
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda
Comenzo, Raymond L., Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Sanchorawala, Vaishali, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Dimopoulos, Meletios A., NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y. ... Merlini, Giampaolo (2020). Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-137582
2020
Conference Publication
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse
Weisel, Katja, Geils, George F., Karlin, Lionel, Mollee, Peter, Chung, Tae-Hoon, Min, Chang-Ki, Sunami, Kazutaka, Goldrick, Amanda, Fang, Belle, Fowler, Jessica and Mateos, Maria-Victoria (2020). Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-133908
2020
Conference Publication
The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Ho, Phoebe Joy, Moore, Elizabeth M., Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrison, Simon J., McDonald, Emma-Jane, McQuilten, Zoe, Wood, Erica M., Mollee, Peter and Spencer, Andrew (2020). The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-141511
2020
Conference Publication
Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance
Boyle, Stephen, Tobin, Joshua W. D., Perram, Jacinta, Hamad, Nada, Barraclough, Allison, Singaraveloo, Lydia, Han, Min-Hi, Blennerhassett, Richard, Nelson, Niles Elizabeth, Johnston, Anna, Talaulikar, Dipti, Karpe, Krishna, Bhattacharyya, Abir, Cheah, Chan Yoon, Subramoniapillai, Elango, Bokhari, Waqas, Lee, Cindy, Hawkes, Eliza A., Gullapalli, Veena, Jabbour, Andrew, Strasser, Simone, Chadban, Steve, Brown, Christina, Mollee, Peter and Hapgood, Greg (2020). Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-140665
2020
Conference Publication
Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study
Landgren, Ola, Weisel, Katja, Dachs, Laura Rosinol, Moreau, Philippe, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Zhang, Jianqi, Go, Ning, Morris, Christopher L. and Usmani, Saad Z. (2020). Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-141291
2020
Conference Publication
An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study
Nicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Nunan, Elizabeth, Woodrow, Carmel, Keating, Eliza, Adlard, Kirsten, Smith, Michelle, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2020). An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study. COSA's 47th Annual Scientific Meeting, Quality and Safety, Implementation Science, Cardio-Oncology, Virtual, 11–13 November 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13499
2020
Journal Article
Physical activity in people with multiple myeloma: associated factors and exercise program preferences
Nicol, Jennifer L., Woodrow, Carmel, Burton, Nicola W., Mollee, Peter, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2020). Physical activity in people with multiple myeloma: associated factors and exercise program preferences. Journal of Clinical Medicine, 9 (10) 3277, 3277-11. doi: 10.3390/jcm9103277
Funding
Past funding
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: